Biotech · Nasdaq · #25 by market cap (snapshot)
Amgen
Price data: TradingView widget below
Loading chart…
Loading chart…
📐 Technicals
Loading chart…
Indicator summary from TradingView (moving averages, oscillators). A mechanical signal, not advice.
📊 Fundamentals
Loading chart…
🏢 Company profile
Loading chart…
📰 Latest AMGN news
Loading chart…
🧩 What it is
Amgen is one of the biggest biotech companies, making medicines for bone health, cancer, inflammation and heart disease, plus biosimilars.
⚡ Why it's interesting
It's a mature biotech with real profits and a dividend. Investors watch its obesity-drug programme closely.
⚠️ Key risks
Patents expire and cheaper biosimilars eat sales. Drug trials can fail, and US drug-pricing policy can cut revenue. It has debt from acquisitions such as Horizon.
👀 What to watch
obesity-drug trial results, biosimilar competition and US drug-price policy. Pipeline news can move it sharply. Dividend investors also watch whether payouts keep growing.
Written by the Hodlia.fi editorial team. Education only — not financial advice, no price predictions.
❓ Amgen FAQ
What is Amgen (AMGN)?
Amgen is one of the biggest biotech companies, making medicines for bone health, cancer, inflammation and heart disease, plus biosimilars.
Why do people follow Amgen?
It's a mature biotech with real profits and a dividend. Investors watch its obesity-drug programme closely.
What are the main risks of Amgen?
Patents expire and cheaper biosimilars eat sales. Drug trials can fail, and US drug-pricing policy can cut revenue. It has debt from acquisitions such as Horizon.
What should I watch with Amgen?
obesity-drug trial results, biosimilar competition and US drug-price policy. Pipeline news can move it sharply. Dividend investors also watch whether payouts keep growing.
Is Amgen a good investment?
Hodlia doesn't give investment advice. Whether Amgen fits you depends on your goals, time horizon and how much loss you can handle. Single stocks can drop a lot even when markets are calm. Read the risks above, compare with a diversified alternative and consider independent advice.